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We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-
Hodgkin’s lymphoma and Hodgkin’s disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of
response was 16 (10–21) weeks. The median overall survival was 70 (9–178) weeks and for responders it was 120 (22–178)
weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients.
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Patients with refractory/relapsed non-Hodgkin’s lymphoma (NHL)
and Hodgkin’s disease (HD), who are not suitable for high-dose
chemotherapy (HDC) or who have relapsed after HDC, have a poor
prognosis with currently available salvage chemotherapy regimens
(El Helw et al, 2000; Shamash et al, 2000). New approaches are
required to improve the prognosis of these patients.
The taxanes (paclitaxel and docetaxel) are a novel group of
cytotoxic compounds with a broad spectrum antitumour activity
and have different mechanisms of action from other chemother-
apeutic agents. They exert their cytotoxic effect by inhibiting
microtubular depolymerisation (Horwitz et al, 1994); with
docetaxel being more potent than paclitaxel (Ringel and Horwitz,
1991). Docetaxel has antiapoptotic and antiangiogenic properties
that may contribute to cytotoxic activity (Haldar et al, 1997;
Hortobagyi, 1999).
Docetaxel has shown significant activity in breast cancer,
nonsmall cell lung cancer and ovarian cancer. (Crown, 1999;
Gandara et al, 1999; Vasey et al, 2001; Markman et al, 2001).
In previous studies; paclitaxel showed some activity in relapsed/
refractory NHL and HD (Wilson et al, 1995; Hopfinger et al, 1996;
Younes et al, 1997, 2001). The experience in the UK with docetaxel
in lymphoma is limited. However, because of its mode of action,
activity in other solid tumours and convenience of administration,
docetaxel is a potentially attractive candidate for evaluation in
NHL and HD.
We report a phase II study of docetaxel in patients with relapsed
and refractory NHL and HD.
PATIENTS AND METHODS
In total, 13 patients recruited into the study had histologically
proven, relapsed or refractory NHL or HD for whom further
conventional chemotherapy was felt to be of little potential benefit.
Patients were excluded if they had central nervous system
lymphomatous involvement. All patients gave informed consent
in accordance with research ethics committee approval. In all, 13
patients were recruited into this trial; their clinical characteristics
are listed in Table 1.
Patients were premedicated with dexamethasone 8mg orally
13h and 1h prior to docetaxel infusion. The antiemetic regimen
was dexamethasone 8mg and granisteron 3mg i.v. before
chemotherapy and dexamethasone 8mg po bd for 4 days following
each cycle. Docetaxel 100mgm
 2 was infused intravenously.
Treatment was repeated every 3 weeks in an outpatient setting.
In response to the findings by other authors that reducing the dose
of docetaxel significantly reduced grade IV neutropenia and febrile
neutropenia in breast and lung cancer patients (Salminen et al,
1999; Fossella et al, 2000), the study protocol was amended and the
final two patients received 70mgm
 2.
Patients were evaluated for treatment response after every
second cycle according to WHO standard criteria. Repeat response
confirmation scans were not performed. Patients with complete
response (CR), partial response (PR) or stable disease (SD) were
continued on treatment for up to six cycles. Patients who had
progressive disease (PD) after any cycle were withdrawn from the
study. A full blood count and biochemistry profile were carried out
weekly.
Dose modification and delay was permitted in the event of some
treatment-related side effects.
STATISTICS
The duration of response dates from beginning of treatment until
evidence of progression. The progression free survival dates from
beginning of treatment until evidence of progression in those who
achieved PR and SD. Overall survival dates from the start of
treatment until death or last follow-up if alive.
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lSPSS software package was used for statistical analysis.
Progression-free survival and overall survival were analysed using
the Kaplan–Meier curves.
RESULTS
Response to treatment
Table 1 summarises the patient’s characteristics and response to
docetaxel. Overall, 12 patients were evaluable for response after
any number of cycles (one to six). There were no complete
responders. After the first two cycles five out of 12 (42%) had PR.
After four cycles, this response was maintained in two patients
(17%). Three (25%) patients had SD after the second cycle of
treatment.
Three out of 12 patients had disease refractory to previous
chemotherapy, one had had PR and the other two patients had SD
after docetaxel treatment. Nine patients had relapsed disease; four
(44%) achieved PR. Four patients had had CR to their previous
chemotherapy; only two out of four achieved PR to docetaxel, but
lasting only for two cycles of therapy.
The median overall survival for all patients was 70 (9–178)
weeks (Figure 1). The median survival for patients with HD was 35
(22–178), HG-NHL 70 (9–125) and for LG-NHL 70 (21–70) weeks
(Figure 2).
The median duration of response was 16 (10–21) weeks and the
median survival 120 (22–178) weeks for responders. Patients
achieving PR or SD had a median progression-free survival of 16.5
(9–30) weeks and median survival of 70 (21–178) weeks.
Four patients had Hodgkin’s disease, two progressed after two
cycles of docetaxel, while two achieved PR. Six patients had HG-
NHL; two, two and two had PR, SD and PD, respectively. Two
patients had LG-NHL; one had PR and one had SD. seven out of 12
(58%) evaluable patients had received HDC and stem cell
transplant before docetaxel; two achieved PR and one SD. Of the
five patients who did not receive prior HDC, three achieved PR and
two SD.
Toxicity (Table 2)
In all, 44 cycles of docetaxel were administered to 13 patients; 42
cycles are assessable for haematological toxicity.
Neutropenia was the commonest haematological toxicity. Nadir
neutropenia was early, in 33 out of 35 cycles (94%) it occurred on
day 7. Grades III and IV neutropenia were observed in 15 and 53%,
respectively, of docetaxel cycles in patients who had received
Table 1 Individual patients’ characteristics, previous treatment, study treatment and response
Age (years)
No of previous
chemotherapy Starting No. of
Response after cycle DOR in PR
PFS in SD+PR Patient Survival
Sex mean =51 regimens Histology dose (mgm
 2) cycles 2 4 6 (weeks) status (weeks)
M 61 1 HG NHL
a 100 5 PR PR PD (After 5) 16 Dead 125
F 53 2 HG NHL
b 100 4 PR PD F 12 Dead 120
M 51 3 (HDC) HG NHL
a 100 1 PD (After 1) FF Dead 9
M 48 3 (HDC) HG NHL
a 100 1 NE FF NE Dead 15
M 55 4 (HDC) HG NHL
b 100 3 SD PD (After 3) F 9 Dead 70
M 57 3 HG NHL
a 100 6 SD SD SD 30 Dead 53
F 56 5 (HDC) HG NHL
a 70 2 PD FF Alive 15
F 42 6 (HDCx2) LG NHL
a 100 2 PR FF 10 Dead 70
M 59 5 LG NHL
b 70 6 SD SD SD 20 Alive 21
F4 72 H D
a 100 4 PR PD F 17 Alive 178
F 27 3 (HDC) HD
a 100 2 PD FF Alive 144
M 53 3 (HDC) HD
a 100 6 PR PR PR 21 Dead 22
F 57 3 (HDC) HD
a 100 2 PD FF Dead 35
HD=Hodgkin’s disease, NHL=non-Hodgkin’s lymphoma, LG=low grade, HG=high grade, M=male, F=female, DOR=duration of response, PFS=progression-free survival,
a=relapsed,
b=refractory, NE=not evaluable, HDC=high dose chemotherapy.
Survival in weeks from starting docetaxel
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Figure 1 Overall survival (n¼13).
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lprevious HDC, and in 48 and 17% of cycles in those who had not
received previous HDC. Recovery of neutrophil count to
41 10
9l
 1 occurred in all cases within 1 week. There was only
one episode of neutropenic sepsis. Toxicity-related (neutropenic
sepsis) dose reduction occurred in only one patient. Treatment was
delayed in only one patient (for 1 week) owing to grade I
thrombocytopenia.
Most nonhaematological toxicities were acceptable and easily
manageable, that is, Grades I and II Table 2. One patient developed
grade III desquamating skin rash which precluded her for
continuing treatment despite having achieved a PR.
DISCUSSION
Docetaxel in this group of heavily pretreated poor prognosis
patients demonstrated PR in 42% of patients after two cycles.
However, responses were short lived; only one patient maintained
such response until after the end of full treatment. Budman et al
(1997) reports 13% major response (CR+PR) and 47% overall
response (CR+PR+SD) in 55 evaluable patients with low and
intermediate grade NHL treated with docetaxel without any steroid
premedication and after only one or two prior chemotherapy
regimens. In our study, dexamethasone was included in the
regimen as premedication and antiemetic treatment. This may
have contributed to the observed antitumour effect. However, such
steroid treatment is considered a generally adopted practice.
Response to treatment did not appear to be influenced by
disease type (HD/NHL), response to previous chemotherapy or
disease status at trial entry. However, patients who had previous
HDC appeared to respond less well to docetaxel. Previous studies
using taxanes report a trend towards a better response in patients
with relapsed as compared to refractory disease. In a phase II
study, 68 patients with low and intermediate grades NHL who had
either relapsed after or failed to respond to chemotherapy were
treated by docetaxel. In low-grade NHL, all of the responses were
seen in the relapsed patients. In intermediate grade NHL, a
response was seen in one of 16 with refractory disease and in four
of five with relapsed disease (Budman et al, 1997). In another
phase II study evaluating paclitaxel in 96 patients with NHL, the
response rates were higher in patients with relapsed than in those
with refractory disease (37 vs 11%), respectively (Younes et al,
1997). In contrast, there was no suggestion of an association
between the response rates to paclitaxel and the presence of
chemotherapy resistant vs sensitive disease (22 vs 15%, respec-
tively) in 31 patients with NHL (Wilson et al, 1995).
The median duration of response was 16 weeks (10–21). This is
comparable to the response reported by Budman et al (1997) (1.4–
20 months). Median survival in weeks decreased from 120 in
responders, to 53 in SD and to 28 in SD and PD together indicating
a poor outcome in nonresponders. However, one patient pro-
gressed after two cycles of docetaxel, but had a CR to subsequent
chemotherapy regimen (ChlVPP) and is now alive and disease free.
After progression on docetaxel 10 out of 13 patients received a
further one or two regimens of chemotherapy (including
rituximab). One of them had HDC and peripheral blood stem cell
rescue. Three out of 13 received radiotherapy with or without
chemotherapy. Two patients received no further anticancer
therapy.
El Helw et al (2001) investigated an anthracycline-based
regimen; VEDex (vincristine, epirubicin, dexamethasone) in
patients with NHL who were heavily pretreated or who had poor
performance status. They reported 66.6% overall response rate and
a median survival of 6 months. Shamash et al (2000) reviewed 37
patients with HD relapsing after HDC treated by a variety of single
and combination chemotherapy. They report a median survival of
8 and 13.5 months, respectively. This compares to median survival
of 35 (22–178) weeks for the four HD patients in our series (Three
out of four received HDC followed by docetaxel). Other studies
have used paclitaxel in NHL patients. Younes et al (1997) and
Wilson et al (1995) reported response rates (CR+PR) of 25 and
27%, respectively. Younes et al (2001) also investigated the
effectiveness of adding another cytotoxic agent (topotecan) to
paclitaxel with 48% overall response rate.
Overall, treatment was well tolerated with the exception of one
patient who developed intolerable skin toxicity. Although neutro-
phil toxicity was common, we had only one episode of neutropenic
sepsis. Fossella et al (2000) compared the use of docetaxel 100 and
75mgm
 2 in previously treated nonsmall cell lung cancer patients
with reduction of grade IV neutropenia from 77 to 54% and febrile
neutropenia from 12 to 8% and recommended the use of
75mgm
 2. Reducing the dose to 70mgm
 2 in two of our patients
prevented grade IV neutropenia in these patients.
CONCLUSION
This small study suggests that the use of moderate dose docetaxel
every 3 weeks for heavily pretreated patients with refractory or
relapsed HD and NHL is feasible, safe and marginally effective.
However, responses are not durable and routine use of single
docetaxel in this setting cannot be recommended. Newer drugs and
approaches are needed to be evaluated in this group of patients.
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Table 2 Haematological and nonhaematological toxicities in relation to number of assessable docetaxel
cycles
Toxicity (no. of cycles) Grade I (%) Grade II (%) Grade III (%) Grade IV (%)
Haemoglobin (42) F 9 (21) FF
Neutrophils (42) 2 (5) 5 (11) 14 (33) 14 (33)
Platelets (42) 3 (7) 1 (2) F 1 (2)
Liver chemistry (42) 4 (10) 1 (2) 1 (2) F
Nausea/Vomiting (44) 3 (7) FFF
Constipation (44) 10 (22) FFF
Diarrhoea (44) 4 (9) FFF
Stomatitis (44) 1 (2) 4 (9) FF
Neuropathy (44) 3 (7) FFF
Fluid retention (44) 3 (7) 2 (5) FF
Skin (44) 3 (7) 2 (5) 1 (2) F
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